Drug intelligence / Profile preview

cafusotide

Development stage: Unknown
Lead developer: Jiangsu Hengrui Medicine
Modality: Peptides
Administration: Intravenous

Overview

Cafusotide (SHR-1103) is a synthetic peptide developed by Jiangsu Hengrui Medicine for the treatment of advanced solid tumors. It acts as an antagonist of the urokinase-type plasminogen activator receptor (uPAR, also known as CD87). By competitively binding to uPAR, cafusotide prevents the interaction between uPAR and its ligand, urokinase-type plasminogen activator (uPA). This interaction is a critical driver of extracellular matrix degradation, tumor cell invasion, and metastasis. Cafusotide was evaluated in Phase 1 clinical trials in China to assess its safety, pharmacokinetics, and preliminary antitumor activity in patients with advanced malignancies.

Other names: cafusotide hydrochloride

Targets

PLAUR (Urokinase plasminogen activator receptor)

Beyond the preview

Go deeper on cafusotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cafusotide.

Explore the full profile